Bat-Erdene Myagmar1, James M Flynn1, Patrick M Cowley1, Philip M Swigart1, Megan D Montgomery1, Kevin Thai1, Divya Nair1, Rumita Gupta1, David X Deng1, Chihiro Hosoda1, Simon Melov1, Anthony J Baker1, Paul C Simpson2. 1. From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.). 2. From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.). paul.simpson@ucsf.edu.
Abstract
RATIONALE: It is unknown whether every ventricular myocyte expresses all 5 of the cardiac adrenergic receptors (ARs), β1, β2, β3, α1A, and α1B. The β1 and β2 are thought to be the dominant myocyte ARs. OBJECTIVE: Quantify the 5 cardiac ARs in individual ventricular myocytes. METHODS AND RESULTS: We studied ventricular myocytes from wild-type mice, mice with α1A and α1B knockin reporters, and β1 and β2 knockout mice. Using individual isolated cells, we measured knockin reporters, mRNAs, signaling (phosphorylation of extracellular signal-regulated kinase and phospholamban), and contraction. We found that the β1 and α1B were present in all myocytes. The α1A was present in 60%, with high levels in 20%. The β2 and β3 were detected in only ≈5% of myocytes, mostly in different cells. In intact heart, 30% of total β-ARs were β2 and 20% were β3, both mainly in nonmyocytes. CONCLUSION: The dominant ventricular myocyte ARs present in all cells are the β1 and α1B. The β2 and β3 are mostly absent in myocytes but are abundant in nonmyocytes. The α1A is in just over half of cells, but only 20% have high levels. Four distinct myocyte AR phenotypes are defined: 30% of cells with β1 and α1B only; 60% that also have the α1A; and 5% each that also have the β2 or β3. The results raise cautions in experimental design, such as receptor overexpression in myocytes that do not express the AR normally. The data suggest new paradigms in cardiac adrenergic signaling mechanisms.
RATIONALE: It is unknown whether every ventricular myocyte expresses all 5 of the cardiac adrenergic receptors (ARs), β1, β2, β3, α1A, and α1B. The β1 and β2 are thought to be the dominant myocyte ARs. OBJECTIVE: Quantify the 5 cardiac ARs in individual ventricular myocytes. METHODS AND RESULTS: We studied ventricular myocytes from wild-type mice, mice with α1A and α1B knockin reporters, and β1 and β2 knockout mice. Using individual isolated cells, we measured knockin reporters, mRNAs, signaling (phosphorylation of extracellular signal-regulated kinase and phospholamban), and contraction. We found that the β1 and α1B were present in all myocytes. The α1A was present in 60%, with high levels in 20%. The β2 and β3 were detected in only ≈5% of myocytes, mostly in different cells. In intact heart, 30% of total β-ARs were β2 and 20% were β3, both mainly in nonmyocytes. CONCLUSION: The dominant ventricular myocyte ARs present in all cells are the β1 and α1B. The β2 and β3 are mostly absent in myocytes but are abundant in nonmyocytes. The α1A is in just over half of cells, but only 20% have high levels. Four distinct myocyte AR phenotypes are defined: 30% of cells with β1 and α1B only; 60% that also have the α1A; and 5% each that also have the β2 or β3. The results raise cautions in experimental design, such as receptor overexpression in myocytes that do not express the AR normally. The data suggest new paradigms in cardiac adrenergic signaling mechanisms.
Authors: J G Meszaros; A M Gonzalez; Y Endo-Mochizuki; S Villegas; F Villarreal; L L Brunton Journal: Am J Physiol Cell Physiol Date: 2000-01 Impact factor: 4.249
Authors: Y Y Zhou; D Yang; W Z Zhu; S J Zhang; D J Wang; D K Rohrer; E Devic; B K Kobilka; E G Lakatta; H Cheng; R P Xiao Journal: Mol Pharmacol Date: 2000-11 Impact factor: 4.436
Authors: Bat-Erdene Myagmar; Taylor Ismaili; Philip M Swigart; Anaha Raghunathan; Anthony J Baker; Sunil Sahdeo; Jonathan M Blevitt; Marcos E Milla; Paul C Simpson Journal: Circ Res Date: 2019-08-20 Impact factor: 17.367
Authors: Javier E López; Janhavi Sharma; Jorge Avila; Taylor S Wood; Jonathan E VanDyke; Bridget McLaughlin; Craig K Abbey; Andrew Wong; Bat-Erdene Myagmar; Philip M Swigart; Paul C Simpson; Nipavan Chiamvimonvat Journal: J Mol Cell Cardiol Date: 2017-08-02 Impact factor: 5.000
Authors: Michael Coronado; Giovanni Fajardo; Kim Nguyen; Mingming Zhao; Kristina Kooiker; Gwanghyun Jung; Dong-Qing Hu; Sushma Reddy; Erik Sandoval; Aleksandr Stotland; Roberta A Gottlieb; Daniel Bernstein Journal: Circ Res Date: 2017-12-12 Impact factor: 17.367
Authors: Regina Celia Spadari; Claudia Cavadas; Ana Elisa T Saturi de Carvalho; Daniela Ortolani; Andre Luiz de Moura; Paula Frizera Vassalo Journal: Cell Mol Neurobiol Date: 2017-10-24 Impact factor: 5.046
Authors: Pierre-Yves Jean-Charles; Samuel Mon-Wei Yu; Dennis Abraham; Reddy Peera Kommaddi; Lan Mao; Ryan T Strachan; Zhu-Shan Zhang; Dawn E Bowles; Leigh Brian; Jonathan A Stiber; Stephen N Jones; Walter J Koch; Howard A Rockman; Sudha K Shenoy Journal: JCI Insight Date: 2017-09-07